IP Library › Assignment 020045/0150
Patent Assignment
Reel/Frame 020045/0150

Assignment of Assignor's Interest

Recorded: 2007-10-25 Pages: 15
Assignors
NPS PHARMACEUTICALS, INC.
Executed: 2007-09-05
ASTRAZENECA AB
Executed: 2007-09-05
Assignee
ASTRAZENECA AB
SE-151 85 SODERTALJE, SODERTALJE, SE-151 85, SWEDEN
Covered Properties (128)
Heteropolycyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Use of MGLUR5 Antagonists for the Treatment of Gerd
New Compounds
New Compounds
New Compounds
New Heterocyclic Compounds
Therapeutic Compounds
Alkynes Iii
Alkynes I
Alkynes Ii
Novel Treatment of Irritable Bowel Syndrome I
Novel Treatment of Gerd Ii
Novel Treatment of Gerd
Nitrogen-Containing Heterocycles Affecting Glutamatergic Synaptic Transmission
New Treatment of Gerd Ii
New Treatment of Gerd I
New Compounds
Additional Heteropolycyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Triazole Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Polyheterocyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Tetrazole Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Fused Heterocyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Isoindolone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
Pyrazolone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
Metabotropic Glutamate-Receptor-Potentiating Isoindolones
Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators
New Use
Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators
Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists
Bicyclic Piperazines as Metabotropic Glutamate Receptor Antagonists
Acetylenic Piperazines as Metabotropic Glutamate Receptor Antagonists
New Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders
Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
Piperazines and Piperidines as MGLUR5 Potentiators
New Metabotropic Glutamate Receptor-Potentiating Isoindolones
Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
MGLUR5 Modulators I
MGLUR5 Modulators Ii
MGLUR5 Modulators Iii
MGLUR5 Modulators Iv
MGLUR5 Modulators V
MGLUR5 Modulators Vi
Heteropolycyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Patent: 6,660,753 →
Application: 10/076,618 →
Publication: US 2003/0055085
Use of MGLUR5 Antagonists for the Treatment of Gerd
Patent: 7,964,609 →
Application: 10/517,869 →
Publication: US 2006/0128760
Therapeutic compounds
Application: 10/549,699 →
Publication: US 2007/0021606
5-Fluoro-, Chloro-and Cyano-Pyridin-2-Yl-Tetrazoles as Ligands of the Metabotropic Glutamate Receptor-5
Application: 10/582,051 →
Publication: US 2007/0255061
Novel Treatment Of Irritable Bowel Syndrome 1
Application: 10/582,388 →
Publication: US 2007/0203163
Fused Heterocyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Application: 10/588,699 →
Publication: US 2007/0185095
Additional Heteropolycyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Application: 10/588,702 →
Publication: US 2007/0179188
Triazole compounds and their use as metabotropic glutamate receptor antagonists
Application: 10/588,751 →
Publication: US 2007/0185178
Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
Application: 10/588,754 →
Publication: US 2007/0185100
Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
Application: 10/588,756 →
Publication: US 2007/0197549
New compounds
Application: 10/636,965 →
Publication: US 2004/0132726
New Compounds
Patent: 7,074,809 →
Application: 10/636,977 →
Publication: US 2004/0106607
Compounds
Application: 10/637,012 →
Publication: US 2004/0152699
Heteropolycyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Patent: 7,112,595 →
Application: 10/699,563 →
Publication: US 2005/0154027
New Metabotropic Glutamate Receptor Compounds
Application: 10/766,948 →
Publication: US 2005/0004130
Additional Heteropolycyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Patent: 7,585,881 →
Application: 11/053,752 →
Publication: US 2005/0272779
Triazole compounds and their use as metabotropic glutamate receptor antagonists
Application: 11/060,366 →
Publication: US 2006/0019997
Tetrazole Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Patent: 7,691,892 →
Application: 11/060,463 →
Publication: US 2006/0004021
Fused Heterocyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Patent: 7,576,077 →
Application: 11/060,560 →
Publication: US 2006/0009443
Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
Application: 11/060,561 →
Publication: US 2006/0025414
New compounds
Application: 11/270,617 →
Publication: US 2006/0063772
Compounds
Patent: 7,456,200 →
Application: 11/274,611 →
Publication: US 2006/0122397
Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
Application: 11/398,556 →
Publication: US 2006/0189661
New use
Application: 11/471,696 →
Publication: US 2007/0010553
Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
Application: 11/490,090 →
Publication: US 2007/0032469
Bicyclic piperazines as metabotropic glutatmate receptor antagonists
Application: 11/498,770 →
Publication: US 2007/0037816
Substituted piperazines as metabotropic glutamate receptor antagonists
Application: 11/498,835 →
Publication: US 2007/0037820
Acetylenic piperazines as metabotropic glutamate receptor antagonists
Application: 11/498,836 →
Publication: US 2007/0037817
Cinnamamide compounds as metabotropic glutamate receptor antagonists
Application: 11/503,182 →
Publication: US 2007/0049578
New Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders
Patent: 7,476,684 →
Application: 11/523,717 →
Publication: US 2007/0129408
Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
Patent: 7,816,354 →
Application: 11/634,250 →
Publication: US 2007/0275966
Isoindolone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
Patent: 7,968,570 →
Application: 11/659,149 →
Publication: US 2009/0275578
mGluR5 modulators II
Application: 11/790,415 →
Publication: US 2007/0259916
mGluR5 modulators III
Application: 11/790,416 →
Publication: US 2007/0259926
MGLUR5 Modulators I
Patent: 7,678,796 →
Application: 11/790,417 →
Publication: US 2007/0259862
MGluR5 modulators VI
Application: 11/790,424 →
Publication: US 2007/0259895
MGluR5 modulators IV
Application: 11/790,428 →
Publication: US 2007/0259923
MGluR5 modulators V
Application: 11/790,429 →
Publication: US 2007/0259860
Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders
Application: 11/793,050 →
Publication: US 2009/0069340
New Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders
Application: 11/829,866 →
Publication: US 2007/0270468
New Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders
Application: 11/829,867 →
Publication: US 2007/0270469
Additional Heteropolycyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Application: 11/840,952 →
Publication: US 2008/0015234
Additional Heteropolycyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Application: 11/840,953 →
Publication: US 2008/0045571
Additional Heteropolycyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Application: 11/840,954 →
Publication: US 2007/0293545
Additional Heteropolycyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists
Application: 11/840,955 →
Publication: US 2008/0015204
Metabotropic Glutamate Receptor Antagonists and Their Use for Treating Central Nervous System Diseases
Application: 60/149,464 →
mGluR antagonists
Application: 60/269,847 →
Compounds exhibiting activity as metabotropic glutamate receptors
Application: 60/402,038 →
Compounds exhibiting activity as metabotropic glutamate receptors
Application: 60/402,039 →
Compounds exhibiting activity as metabotropic glutamate receptors
Application: 60/402,040 →
New compounds
Application: 60/443,889 →
Therapeutic compounds
Application: 60/462,697 →
New heterocyclic compounds
Application: 60/530,632 →
Nitrogen-containing heterocycles affecting glutamatergic synaptic transmission
Application: 60/530,633 →
Triazole compounds and their use as metabotropic glutamate receptor antagonists
Application: 60/545,289 →
Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
Application: 60/545,291 →
Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
Application: 60/545,292 →
Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
Application: 60/545,580 →
Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
Application: 60/601,125 →
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
Application: 60/608,960 →
Pyrazolone compounds and their use as metabotropic glutamate receptor potentiators
Application: 60/638,369 →
Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
Application: 60/684,945 →
New use
Application: 60/694,242 →
New use
Application: 60/695,417 →
Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
Application: 60/705,471 →
Acetylenic piperazines as metabotropic glutamate receptor antagonists
Application: 60/707,944 →
Bicyclic piperazines as metabotropic glutatmate receptor antagonists
Application: 60/707,945 →
Substituted piperazines as metabotropic glutamate receptor antagonists
Application: 60/707,946 →
Cinnamamide compounds as metabotropic glutamate receptor antagonists
Application: 60/710,608 →
New compounds
Application: 60/721,527 →
Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
Application: 60/750,347 →
Piperazines and piperidines as mGluR5 potentiators
Application: 60/758,992 →
Metabotropic glutamate receptor-potentiating isoindolones
Application: 60/773,870 →
Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators
Application: 60/787,634 →
New compounds I
Application: 60/797,659 →
New compounds II
Application: 60/797,660 →
New compounds IV
Application: 60/797,662 →
New compounds V
Application: 60/797,663 →
New compounds VI
Application: 60/797,664 →
New compounds III
Application: 60/797,665 →
New Metabotropic Glutamate Receptor-Potentiating Isoindolones
Application: 60/871,590 →
PIPERAZINE AND PIPERIDINE mGluR5 POTENTIATORS
Application: 60/894,114 →
Aza-isoindolones and their use as metabotropic glutamate receptor potentiators
Application: 60/900,318 →
Hydrazides and Their Use as Metabotropic Glutamate Receptor Potentiators
Application: 60/912,346 →
Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators-842
Application: 60/942,553 →
Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators-841
Application: 60/942,556 →
Related Assignments (14)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Apr 4, 2002
From: VAN WAGENEN, BRADFORD C.; STORMANN, THOMAS M.; MOE, SCOTT T.; SHEEHAN, SUSAN M.
To: NPS PHARMACEUTICALS, INC.
Reel/Frame 012758/0798 →
Assignment of Assignor's Interest Oct 12, 2005
From: LEHMANN, ANDERS; MATTSSON, JAN; STORMANN, THOMAS M.
To: ASTRAZENECA AB; NPS PHARMACEUTICALS
Reel/Frame 017075/0656 →
Assignment of Assignor's Interest Jan 6, 2006
From: NPS PHARMACEUTICALS
To: ASTRAZENECA AB
Reel/Frame 016982/0383 →
Assignment of Assignor's Interest Jan 6, 2006
From: VAN WAGENEN, BRADFORD; STORMANN, THOMAS M.; MOE, SCOTT T; SHEEHAN, SUSAN M
To: NPS PHARMACEUTICALS; ASTRAZENECA AB
Reel/Frame 016982/0393 →
Corrective Assignment to Correct the Assignee Information Previously Recorded on Reel 016982 Frame 0383. Assignor(S) Hereby Confirms the Assignees Should Be Listed as: Astrazeneca Ab and Nps Pharmaceuticals, Inc.. Jan 30, 2006
From: NPS PHARMACEUTICALS, INC.
To: NPS PHARMACEUTICALS, INC.; ASTRAZENECA AB
Reel/Frame 017087/0681 →
Assignment of Assignor's Interest Jul 17, 2006
From: EGLE, IAN; FREY, JENNIFER; ISAAC, METHVIN; SLASSI, ABDELMALIK
To: ASTRAZENECA AB; NPS PHARMACEUTICALS, INC.
Reel/Frame 017951/0253 →
Assignment of Assignor's Interest Sep 7, 2007
From: UKKIRAMAPANDIAN, RADHAKRISHNAN; CLAYTON, JOSHUA; EGLE, IAN; ISAAC, METHVIN
To: NPS PHARMACEUTICALS, INC.
Reel/Frame 019798/0599 →
Assignment of Assignor's Interest Sep 7, 2007
From: EMPFIELD, JAMES; STEELMAN, GARY; URBANEK, REBECCA; WALSH, SALLY
To: ASTRAZENECA AB
Reel/Frame 019798/0859 →
Assignment of Assignor's Interest Sep 10, 2007
From: UKKIRAMAPANDIAN, RADHAKRISHNAN; CLAYTON, JOSHUA; EGLE, IAN; ISAAC, METHVIN
To: NPS PHARMACEUTICALS, INC.
Reel/Frame 019803/0299 →
Assignment of Assignor's Interest Sep 10, 2007
From: EMPFIELD, JAMES; STEELMAN, GARY; URBANEK, REBECCA; WALSH, SALLY
To: ASTRAZENECA AB
Reel/Frame 019803/0292 →
An Assignment of Equal and Undivided Share Sep 10, 2007
From: NPS PHARMACEUTICALS, INC.
To: ASTRAZENECA AB; NPS PHARMACEUTICALS, INC.
Reel/Frame 019802/0512 →
An Assignment of Equal and Undivided Share Sep 10, 2007
From: ASTRAZENECA AB
To: NPS PHARMACEUTICALS, INC.; ASTRAZENECA AB
Reel/Frame 019802/0498 →
An Assignment of Equal and Undivided Share Sep 11, 2007
From: ASTRAZENECA AB
To: NPS PHARMACEUTICALS, INC.; ASTRAZENECA AB
Reel/Frame 019806/0456 →
An Assignment of Equal and Undivided Share Sep 11, 2007
From: NPS PHARMACEUTICALS, INC.
To: ASTRAZENECA AB; NPS PHARMACEUTICALS, INC.
Reel/Frame 019806/0435 →